Embedded Files
COVID-19 自爆發以來，在全球皆造成重大的影響，急需找尋合適的藥物來進行有效的治療，新藥開發從合成開始到臨床測試所費不貲且耗時極為漫長，對於疫情已經緩不濟急，藉由找尋老藥新用途來開發 COVID-19 的醫療藥物，可能是更好的選擇。
VF-101 是藉由大數據分析所找出的一個候選具有潛在性的食品配方。研究發現 VF-101 能抑制 COVID-19 的 3CL 水解酵素酶的活性，能修復由 Bleomycin 所造成的實驗鼠肺損傷，並提升實驗鼠的血氧濃度，也可以抑制巨噬細胞，進行鐵依賴型（Ferroptosis）的細胞死亡，以上研究成果顯示 VF-101 具有緩解急性呼吸窘迫症候群 ( ARDS ) 的可能性，我們將申請進行人體試驗測試。
Since the outbreak of COVID-19, it has had a significant impact on the world. It is urgent to find suitable drugs for effective treatment. The development of new drugs from the start of synthesis to clinical testing is costly and time-consuming. The epidemic has been slowed down. It may be a better choice to develop medical drugs for COVID-19 by finding new uses for old drugs.
VF-101 is a potential food candidate identified by big data analysis. Studies have found that VF-101 can inhibit the activity of the 3CL hydrolase enzyme of COVID-19, repair the lung damage of experimental rats caused by Bleomycin, and increase the blood oxygen concentration of experimental rats. It can also inhibit macrophages to perform ( Ferroptosis) Cell death, the above research results show that VF-101 has the possibility of remission Acute Respiratory Distress Syndrome ( ARDS ), and we will apply for human trial testing.
治療新冠肺炎必須同時解決下列三項問題
一、減少病毒數量《擊殺病毒》
二、預防急性呼吸窘迫症候群 ( ARDS )《血氧含量》
三、預防細胞激素釋放症候群 ( CRS )《免疫風暴》
To treat COVID-19 the following three issues must be addressed at the same time
1 . Reduce the number of viruses
2 . Prevention of Acute Respiratory Distress Syndrome ( ARDS )
3 . Prevent Cytokine Release Syndrome ( CRS )
冠狀病毒如何進入人體細胞將病毒 RNA 插入宿主？
How does the Coronavirus enter a human cell to insert the viral-RNA into the host?
透過生物晶片與大數據分析『 VF-101 』為潛力治療藥物
我們目標是針對 COVID-19 引發的急性呼吸窘迫症候群（Acute respiratory distress syndrome, ARDS），透過次世代基因偵測技術 RNAseq 以及基因表現圖譜檢測平台- CLUE 數據庫來推動” 老藥新用” 的藥物保健食品開發。此系統為大規模串聯疾病、基因與藥物三者之間的關聯性並形成強而有力互聯網平台。共收集了 132 萬筆經由 L1000 測得的基因微陣列資料（包含超過 20,000 個小分子藥物的基因表現圖譜資料），同時我們也擁有 1.2 萬筆不同藥物及保健食品的基因表現圖譜資料庫。
另外整合多種生物和疾病途徑數據庫（KEGG，Gene Ontology，Disease Ontology，GSEA）以更深度、精準預測方式篩選出『 VF-101 』為有潛在逆轉SARS-CoV-2 與急性呼吸窘迫症候群的藥物以治療 COVID-19。
Potential mechanisms of VF-101 from KEGG
Our goal is to target Acute respiratory distress syndrome ( ARDS ) caused by COVID-19, and promote "old medicines and new use" medicine health care through the Next Generation Sequencing (NGS) gene detection technology ( RNAseq ) and gene expression profile detection platform-CLUE database Food development. This system is a large-scale connection between diseases, genes and drugs and forms a powerful Internet platform. A total of 1.32 million gene microarray data ( including gene expression profile data of more than 20,000 small molecule drugs ) measured by L1000 were collected. At the same time, we also have a database of 12,000 gene expression profiles of different drugs and health foods.
In addition, it integrates multiple biological and disease pathway databases ( KEGG, Gene Ontology, Disease Ontology, GSEA ) to screen out "VF-101" as a drug that has the potential to reverse SARS-CoV-2 and acute respiratory distress syndrome in a more in-depth and accurate predictive manner for treatment COVID-19.
摘要
COVID-19 是一種複雜的疾病，多靶向藥物比單靶向藥物更具優勢。
我們的藥物篩選平台進行了高通量篩選方法，結果表明 VF-101 通過調節 microRNA(miRNA) 水平和鐵代謝相關途徑逆轉了 COVID-19 和 ARDS 的基因特徵。
VF-101 和 Hopkinpro 可以上調 Let-7a 的表達。
VF-101 可以顯著抑制 TNF-α 的釋放，而 Hopkinpro 可以輕微抑制 IL-1β 的分泌。
VF-101 和 Hopkinpro 抑制 SARS-CoV-2 Mpro 的 IC50 分別為 19.71 ± 43.94 和 19.33 ± 30.15 µg/ml。
VF-101 在 SpO2 和呼吸頻率方面，對急性呼吸窘迫症候群的實驗鼠有改善作用。
Summary
COVID-19 is a complex disease that multi-targeted drugs are more advantageous than single-targeted drugs.
High-throughput screening approaches are performed by our drug screening platform and showed that VF-101 reversed the gene signature of COVID-19 and ARDS by regulating microRNA (miRNA) levels and iron metabolism-related pathways.
VF-101 and Hopkinpro could up-regulate Let-7a expression.
TNF-α release could be significantly inhibited by VF-101, while IL-1β secretion was slightly suppressed by Hopkinpro.
The IC50 to inhibit SARS-CoV-2 Mpro of VF-101 and Hopkinpro were 19.71 ± 43.94 and 19.33 ± 30.15 µg/ml, respectively.
VF-101 showed improving effect on ARDS rat model in term of SpO2 and breathe frequency.
Page updated
Google Sites
Report abuse